Ocular allergy treatment comparisons: azelastine and olopatadine.
Azelastine hydrochloride 0.05% and olopatadine hydrochloride 0.1% are topical ocular allergy treatments that have demonstrated multiple pharmacologic actions, including antihistamine, mast cell stabilization, and inhibition of proinflammatory mediators. In this article, the mechanisms of action, efficacy, and tolerability of these two agents on ocular signs and symptoms are examined. By studying the various target sites of drug action, an enhanced clinical response algorithm of these topical ocular agents can be implemented to maximize the response for patients suffering from ocular allergy.
Bielory
Leonard
L
Department of Medicine & Pediatric Ophthalmology, UMDNJ-New Jersey Medical School, Newark, 07103, USA. bielory@umdnj.edu
Buddiga
Praveen
P
Bigelson
Stephen
S
D000287:Administration, Topical; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism; D000069605:Olopatadine Hydrochloride; D010793:Phthalazines / Q000627:therapeutic use*
D018926:Anti-Allergic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003990:Dibenzoxepins; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D010793:Phthalazines; D000069605:Olopatadine Hydrochloride; C020976:azelastine